Progress on the drugs for regulating high-density lipoprotein

Abstract

Abstract: Atherosclerosis (AS) is pathologically important basis of many kinds of coronary atherosclerosis disease (CAD).It can be substantially protected by raising high-density lipoprotein (HDL).In view of mechanism, drugs for raising HDL include:cholesterol ester transfer protein inhibitors, peroxisomal proliferator-activated receptor agonists, liver X-activated receptor agonists, farnesoid X receptor antagonists or agonists, lipoprotein lipase activators, niacin, and phenytoin and lecin:cholesterol acyltransferase activators, etc.This review aimed to the progress of drugs for regulating highdensity lipoprotein and their mechanism, in view of clinical and preclinical aspects.

Key words: high-density lipoprotein(HDL), atherosclerosis(AS), coronary atherosclerosis disease (CAD), apolipoprotein, cholesterol ester transfer protein(CETP), peroxisomal proliferator-activated receptor (PPAR), lipoprotein lipase(LPL) 9129

CLC Number:

R972.6
R969

LI Qin-Kai, YIN Wei-Dong. Progress on the drugs for regulating high-density lipoprotein[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(8): 841-844.

References

1 Brousseau ME, O’Connor JJ Jr, Ordovas JM, Collins D, Otvos JD, Massov T, et al.Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency :Veterans Affairs HDL Cholesterol Intervention Trial[J].Arterioscler Thromb Vasc Biol, 2002;22(7):1148-54
2 Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, et al.Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol[J].N Engl J Med, 2004;350(15):1505-15
3 Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-Aryitey G, et al.Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein:an initial multidose study of torcetrapib[J].Arterioscler Thromb Vasc Biol, 2004;24(3):490-7
4 Chinetti G, Gbaguidi FG, Griglio S, Mallat Z, Antonucci M, Poulain P, et al.CLA-Ⅰ SR-B Ⅰ is expressed in atherosclerotic lesion macrophages and by activators of peroxisomal proliferator-activated receptors[J].Circulation, 2000;101(20):2411-2417
5 Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, et al.PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway[J].Nat Med, 2001;7(1): 53-8
6 Chinetti G, Lestavel S, Fruchart JC, Clavey V, Staels B.Peroxisome proliferator-activated receptor αreduces cholesterol esterification in macrophages[J].Cir Res, 2003;92(2):212-7
7 Nyman JA, Martinson MS, Nelson D, Nugent S, Collins D, Wittes J, et al.VA-HIT Study Group .Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol:the department of veterans affairs high-density lipoprotein cholesterol intervention trial[J].Arch InternMed, 2002;162(2):177-82
8 Oliver WR Jr, Shenk JL, SnaithMR, Russell CS, Plunket KD, Bodkin NL, et al.A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport[J]. Proc Natl Acad Sci USA, 2001;98(9):5306-11
9 Lund EG, Menke JG, Sparrow CP.Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis[J].Arterioscler Thromb Vasc Biol, 2003;23(7):1169-77
10 Miao B, Zondlo S, Gibbs S, Cromley D, Hosagrahara VP, Kirchgessner TG, et al.Raising high-density lipoprotein cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator[J].J Lipid Res, 2004;45(8):1410-7
11 Wagner BL, Valledor AF, Shao G, Daige CL, Bischoff ED,Petrowski M, et al.Promoter-specific roles for liver X receptor corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression[J].Mol Cell Biol, 2003;23(16):5780-9
12 Li S, Zhang ZW, Guan YF.On the bile acid receptor FXR[J].Sheng Li Ke Xue Jin Zhan, 2003;34(4):314-8
13 Cui J, Huang L, Zhao A, Lew JL, Yu J, Sahoo S, et al.Guggulsterone is a farnesoid X receptor antagonist in coactivator association assay s but acts to enhance transcription of bile salt export pump[J].J Bio Chem, 2003;278(12):10214-2014
14 Yin W, Liao D, Kusunoki M, Xi S, Tsutsumi K, Wang Z, et al.NO-1886 decreases ectopic lipid deposition and protects pancreatic beta cells in diet-induced diabetic swine[J].J Endocrinol,2004;180(3):399-408
15 YinW, Tsutsumi K.Lipoprotein lipase activator NO-1886[J].Cardiovasc Drug Rev, 2003;21(2):133-42
16 YinW, Yuan Z, Tsutsumi K, Xie Y, Zhang Q, Wang Z, et al.A lipoprotein lipase-promoting agent, NO-1886, improves glucose and lipid metabolism in high fat, high sucrose-fed new zealand white rabbits[J].Int J Exp Diabesity Res, 2003;4(1):27-34
17 Trocho C, Escola-Gil JC, Ribas V, Benitez S, Martin-Campos JM, Rotllan N, et al.Phenytoin treatment reduces atherosclerosis in mice through mechanisms independent of plasma HDLcholesterol concentration[J].Atherosclerosis, 2004;174(2):275-85
18 Franceschini G, Werba JP, D’Acquarica AL, Gianfranceschi G, Michelagnoli S, Sirtori CR.Microsomal enzyme inducers raise plasma high-density lipoprotein cholesterol levels in healthy control subjects but not in patients with primary hypoalphalipoproteinemia[J].Clin Pharmacol Ther, 1995;57(4):434-40
19 Goerdt C, Keith M, Rubins HB.Effect of phenytoin on plasma high-density lipoprotein cholesterol level in mem with low levels of high-density lipoprotein cholesterol[J].J Clin Pharmacol, 1995;35(8):767-75

[1]	FAN Yao, XUE Yong, WANG Xin, CHEN Xuefei, ZHANG Xu, YAO Yingshui, SHEN Chong. Association analysis of apolipoprotein E polymorphisms and weight loss among schizophrenia patients with risperidone treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 288-295.
[2]	CHEN Xiang-pan, YANG Jie-ren, LIU Yan, HAO Wei, LI Xian-wei. Effect of sequoyitol on lipid metabolism in type 2 diabetic rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(6): 633-637.
[3]	DING Jie-wei¹, WANG Jian-ping². Effects of atorvastatin on ApoA-I and SR-B1 in ApoE-deficient mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(11): 1233-1237.
[4]	QIN Yan-wen, YE Ping, WANG Lu-ya, YANG Ya. Primary prevention effect of atorvastatin on myocardial hypertrophy in ApoE-deficient (ApoE-/-) mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(1): 48-51.